TransMedics Group (TMDX) Expected to Announce Quarterly Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) is anticipated to release its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect TransMedics Group to post earnings of $0.41 per share and revenue of $155.2790 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

TransMedics Group Stock Performance

TransMedics Group stock opened at $134.25 on Monday. TransMedics Group has a 12-month low of $62.07 and a 12-month high of $156.00. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The company has a market capitalization of $4.59 billion, a price-to-earnings ratio of 54.35 and a beta of 2.06. The firm’s fifty day moving average price is $132.50 and its 200 day moving average price is $125.92.

Insiders Place Their Bets

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the sale, the insider owned 13,955 shares in the company, valued at $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,920 shares of company stock valued at $1,257,310 over the last 90 days. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently modified their holdings of the company. Harvest Fund Management Co. Ltd bought a new stake in TransMedics Group in the 3rd quarter valued at about $29,000. Allworth Financial LP grew its position in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the period. US Bancorp DE raised its holdings in shares of TransMedics Group by 24.2% during the third quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after buying an additional 104 shares during the last quarter. Finally, Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group during the fourth quarter valued at approximately $61,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TMDX shares. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Needham & Company LLC lifted their price objective on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Morgan Stanley lifted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.